TG Therapeutics, Inc.
NEWS
Even with a holiday week, July 4, there were a number of clinical trial reports. Here’s a look.
Overall response rate (ORR) of 52% (N=42), with complete response (CR) rate of 19%, by central independent review committee (IRC)
Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired TG Therapeutics, Inc. securities from June 4, 2018 through September 25, 2018
TG Therapeutics and Novimmune SA struck a collaborative deal worth up to $185 million on the development and commercialization of a treatment for hematologic B-cell malignancies.
A look at three biotech companies that face make-or-break catalysts this year.
JOBS
IN THE PRESS